Baby Kataria

Baby Kataria

Auto-generated profile, based on publicly available information

Baby Kataria


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ARAshi Ramavat
Ashi Ramavat
PAPriya Antil
Priya Antil
SKSoniya Kaushik
Soniya Kaushik
BKBaby Kataria
Baby Kataria
Ramendra Pati PandeyRamendra Pati Pandey
Ramendra Pati Pandey
Nanomedicine has now become a transformative platform that enhances the precision and efficacy of immunotherapy approaches and allows customizations like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nanoscale, researchers have been able to manipulate immune responses operating across spatial and temporal scales to address key limitations of conventional immunotherapy associated with working with immune response such as immune evasion, systemic toxicity, and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens, and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation, and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.

29 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSheetal Kundu
Sheetal Kundu
DKDiksha K
Diksha K
SKSwati K
Swati K
TKTamana K
Tamana K
BKBaby K
Baby K
Ramendra Pati PandeyRamendra Pati Pandey
Ramendra Pati Pandey
Recent advancements in gut microbiome research have highlighted the complex interplay between gut microbiota and various physiological and pathological processes, showing that gut microbiota plays a vital role in human health and disease. Imbalances in the gut microbiota, known as dysbiosis, have been associated with a range of health conditions, including gastrointestinal disorders, metabolic diseases, etc. In response to these findings, probiotics, prebiotics, synbiotics, and postbiotics have emerged as a promising therapeutic strategy to modulate gut microbiota composition and functionality. This review paper explores the latest research on how gut microbiota impacts host physiology, immune responses, and overall well-being. Furthermore, the paper delves into the therapeutic potential of probiotics, postbiotics, prebiotics, and synbiotics in therapeutic applications and curing various diseases. The paper also addresses the challenges and opportunities in the field, highlighting the need for personalized approaches to probiotic therapy and the importance of considering factors such as strain specificity, dosing, and safety.Overall, this review aims to provide a comprehensive overview of the evolving landscape of gut microbiota and probiotics, prebiotics, synbiotics, and postbiotics as novel therapeutic agents. It underscores the potential of harnessing the gut microbiome to improve health, prevent diseases, and complement traditional medical interventions. As research in this field continues to expand, a deeper understanding of the gut microbiota and probiotics, prebiotics, synbiotics, and postbiotics promises new avenues for preventive and therapeutic healthcare strategies.

18 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BKBaby Kataria
Baby Kataria
SKSheetal Kundu
Sheetal Kundu
RKRohit Kumar
Rohit Kumar
RDRuby Dhiman
Ruby Dhiman
Ramendra Pati PandeyRamendra Pati Pandey
Ramendra Pati Pandey
APAnjali Priyadarshini
Anjali Priyadarshini
Background: Probiotics have been found to be beneficial for human beings through the modulation of intestinal bacteria and inhibition of pathogens. In light of the increased prevalence of multidrug resistant uropathogens, there is a need for alternative therapies than antibiotics. Objectives: This study assessed the capacity of three probiotics (Lactobacillus acidophilus, Lactic Acid Bacillus and Probiotic Consortium) to inhibit three important uropathogens; Escherichia coli, Klebsiella and Staphylococcus aureus with a view of understanding their antibacterial mechanism of action. Methods: In vitro co-cultures were set up to monitor the growth of the pathogens, the development of biofilms and acidification of the culture media for 24 hours. Biofilm biomass inhibition was assessed using crystal violet microtiter plate assays. The molecular responses to probiotics of Escherichia coli was also assessed by analysis of transcriptomics of cell envelope stress genes (omp) and molecular chaperones (dnaK, chap). Results: The efficacy of biofilm inhibition was highly strain-dependent, such that Lactobacillus acidophilus always showed significantly greater broad spectrum biofilm inhibition than both the probiotic consortium and Lactic Acid Bacillus. Escherichia coli Biofilm Inhibition: L. acidophilus gave the highest inhibition of 66.67%, whereas the probiotic consortium inhibited 59.05% of the biofilms and Lactic Acid Bacillus 3.81%. Klebsiella Biofilm Inhibition: The best biofilm inhibition was observed with L. acidophilus with 78.00% compared to the probiotic consortium (61.11%) and Lactic Acid Bacillus (42.50%). Staphylococcus aureus Biofilm Inhibition: L. acidophilus showed maximal biofilm inhibition of 69.09% compared to 54.55% inhibition from the probiotic consortium. Inhibition showed high correlation with medium acidification and antimicrobial metabolite production. Transcriptome analysis: treatment with L. acidophilus caused severe cell envelope stress in E. coli (5.4-fold increase in expression of omp) and impaired intracellular stress response in E. coli with the inhibition of molecular chaperone (dnaK -4.0-fold and chap -2.6-fold. Conclusion: Lactobacillus acidophilus is a strong broad spectrum antibiofilm agent that targets Gram-negative and Gram-positive uropathogens. Antimicrobial activity of this bacterium is exerted through acidification, metabolite production, cell envelope stress induction, and regulation of stress response mechanisms.

14 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ARAshi Ramavat
Ashi Ramavat
PAPriya Antil
Priya Antil
SKSoniya Kaushik
Soniya Kaushik
BKBaby Kataria
Baby Kataria
Ramendra Pati PandeyRamendra Pati Pandey
Ramendra Pati Pandey
Nanomedicine has now become a radical agent of change in the game of immunotherapy and introduced precision, control, and customization like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nano scale, researchers have been able to manipulate immune responses by working on a scale both spatial and temporal in such a way that it helps overcome the drawbacks associated with working with immune response such as immune evasion, systemic toxicity and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.